These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 20399641

  • 1. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F, Arndt K, Gambacorti-Passerini C.
    Eur J Cancer; 2010 Jul; 46(10):1781-9. PubMed ID: 20399641
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH.
    Recent Results Cancer Res; 2014 Jul; 201():81-97. PubMed ID: 24756786
    [Abstract] [Full Text] [Related]

  • 6. Bosutinib.
    Keller G, Schafhausen P, Brümmendorf TH.
    Recent Results Cancer Res; 2010 Jul; 184():119-27. PubMed ID: 20072835
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F, Piazza R, Vagge E, Gambacorti-Passerini C.
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [Abstract] [Full Text] [Related]

  • 11. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW.
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [Abstract] [Full Text] [Related]

  • 12. An update on dual Src/Abl inhibitors.
    Musumeci F, Schenone S, Brullo C, Botta M.
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [Abstract] [Full Text] [Related]

  • 13. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V, Wang A, Prescott H.
    Am J Health Syst Pharm; 2015 Mar 15; 72(6):439-47. PubMed ID: 25736937
    [Abstract] [Full Text] [Related]

  • 14. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S, Brullo C, Musumeci F, Botta M.
    Expert Opin Investig Drugs; 2010 Aug 15; 19(8):931-45. PubMed ID: 20557276
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.